Effect of prophylactic anticoagulation on the incidence of venous thromboembolism in patients with testicular germ cell tumor.

Nikola Hapakova
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Michal Chovanec
Comenius University, Faculty of Medicine; National Cancer Institute, Bratislava, Slovakia

Katarina Rejlekova
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Katarina Kalavska
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Jana Obertova
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Patrik Palacka
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Valentina De Angelis
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Zuzana Sycova-Mila
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Jozef Mardiak
Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovakia

Michal Mego (misomego@gmail.com)
2nd Department of Oncology, Comenius University, Faculty of Medicine, National Cancer Institute

Research article

**Keywords:** testicular germ cell tumors, venous thromboembolism, low-molecular-weight heparin, prophylaxis, chemotherapy

**DOI:** https://doi.org/10.21203/rs.3.rs-20044/v2

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background Testicular germ cell tumors (GCTs) are among the most common solid tumors in young males. With the availability of highly effective treatment, improving patients’ quality of life has gained more focus in recent years. Venous thromboembolism (VTE), commonly occurring in patients with GCT, is associated with increased morbidity and mortality. Prophylactic anticoagulation has been shown to decrease the risk of VTE in patients with malignancy. The aim of this retrospective study was to evaluate the effect of low-molecular-weight heparin (LMWH) prophylaxis on the incidence of VTE and outcome in patients with GCT treated with first-line chemotherapy.

Methods Our study population included chemotherapy-naive patients with GCT treated with first-line chemotherapy at the National Cancer Institute, Bratislava, Slovakia, from January 2000 to December 2017. VTE was defined as any venous thrombosis or pulmonary embolism, confirmed by imaging, occurring during first-line chemotherapy. Patients diagnosed with VTE on initial staging exam were excluded from the study. No visceral thromboses were observed.

Results Our cohort included 353 patients with GCT. LMWH prophylaxis was administered to 104 patients (29.5%), and 249 patients (70.5%) did not receive prophylaxis. We observed 14 (4.0%) VTE events. The difference in VTE incidence between patients with and without prophylaxis was not statistically significant (5.8% vs. 3.2% P = 0.37). We observed a trend toward longer overall survival in patients without prophylaxis (hazard ratio = 0.61, 95% confidence interval = 0.32-1.13, p = 0.08). Patients with extragonadal GCT receiving VTE prophylaxis had significantly shorter survival (hazard ratio = 0.29, 95% confidence interval = 0.08-1.12, P = 0.04). This effect was most likely driven by a higher incidence of treatment-related deaths in patients with extragonadal GCT receiving LMWH ( P = 0.06). Conclusions LMWH prophylaxis was not associated with decreased VTE incidence. Moreover, there was a higher incidence of treatment-related deaths in patients with extragonadal tumor location. LMWH prophylaxis during hospitalization should not be used routinely in patients with GCT receiving chemotherapy.

Background

Testicular germ cell tumors (GCTs) represent one of the most common solid neoplasms in young males between the ages of 15 and 35 and the incidence has been steadily rising in the past decades.[1, 2] Cisplatin-based chemotherapy with or without resection of the residual mass are highly effective in the treatment of GCTs with five-year survival rate of more than 95%.[3] As a result, the number of GCT survivors with long life expectancy is rising. Therefore, maintaining patients’ quality of life and minimizing treatment-related morbidity and mortality has gained more significant interest in recent years.

Venous thromboembolism (VTE) commonly occurs in cancer patients.[4] It affects about 10% of patients with malignancy. The pathophysiology is thought to be multifactorial and is related to the type of tumor, anatomic location, patient's comorbidities, type of treatment, etc.[5] When compared to patients with different type of malignancy, GCT patients have higher incidence of VTE events.[6]
VTE is associated with increased morbidity and mortality in cancer patients. Levitan et al found more than a threefold higher risk of recurrent VTE and death in cancer patients compared to patients with VTE without cancer diagnosis.[7]

Incidence of VTE in GCT patients has been assessed in a few studies and the results vary widely. Honecker et al observed 9% VTE incidence in patients before starting chemotherapy, while there was only a 2% incidence of VTE during first-line chemotherapy.[8] In a different study, Piketty et al found a 14% incidence of VTE during first-line chemotherapy and 5% incidence of VTE after chemotherapy.[6]

Several groups focused on identification of risk factors of VTE events in GCT patients.[6, 9-12] Weijl et al observed an increased risk of VTE in patients with liver metastases (odds ratio = 4.9).[10] Piketty et al identified body surface area > 1.9m$^2$ (relative risk (RR) = 5, 95% confidence interval (CI) 1.8-13.9) and elevated serum lactate dehydrogenase (RR = 6.4, 95% CI 2.3-18.2) as independent risk factors. In their study, patients without any risk factors had 4% probability of having VTE, while patients with at least 1 risk factor had 26% probability of having VTE.[6]

Prophylactic anticoagulation has been shown to decrease the risk of symptomatic VTE in cancer patients. (RR = 0.56, 95% CI 0.47-0.68) [13] Gizzi et al studied the incidence of thromboembolic events in GCT patients treated with first-line chemotherapy and observed lower incidence of thromboembolic events in patients receiving thromboprophylaxis when compared to patients without prophylaxis.[12] However, small number of patients in each subgroup of this study makes the interpretation of the results difficult and larger study is needed to elucidate the relationship between thromboprophylaxis and incidence of VTE in GCT patients undergoing cisplatin-based chemotherapy.

The aim of this retrospective study was to evaluate the effect of low molecular weight heparin (LMWH) prophylaxis on incidence of VTE events and outcome in germ cell tumor patients treated with first-line chemotherapy.

**Methods**

**Study patients**

This retrospective study was conducted using the National Cancer Institute medical records database. The study was approved by the Institutional Review Board, and a waiver of consent form was granted. Patients diagnosed with germ cell tumors treated with first-line/adjuvant chemotherapy at the National Cancer Institute, Bratislava, Slovakia, from January 2000 to December 2017 were eligible. Patients with any concurrent malignancy other than nonmelanoma skin cancer in the previous 5 years were excluded from the study. Patients with previous chemotherapy, venous thromboembolism diagnosed on the initial staging exam and anticoagulation therapy (therapeutic or prophylactic) started before the initiation of first-line chemotherapy were excluded.
Definition of VTE event

VTE events were defined as any venous thrombosis or pulmonary embolism occurring between Day 1 of the first cycle of first-line chemotherapy and Day 21 of the last cycle of first-line chemotherapy. Cases of superficial phlebitis were not classified as events. Every VTE event had to be confirmed by imaging studies, either Doppler ultrasonography or a CT scan. Depending on the patients’ presenting symptoms, the events were divided into symptomatic and incidental if discovered on imaging performed for a different purpose. The Khorana score was calculated as described previously.\textsuperscript{[14]}

Baseline data

During the initial staging, patients had a CT scan of the chest, abdomen and pelvis. Baseline data regarding age, primary tumor location, tumor histology, TNM stage, International Germ Cell Cancer Collaborative Group (IGCCCG) risk class and first-line chemotherapy regimen were recorded. Blood coagulation tests were not routinely performed during the initial screening.

VTE prophylaxis

LMWH prophylaxis was not routinely prescribed before January 2010 during hospitalization. At our institution, all patients with GCT are hospitalized during chemotherapy. In December 2007, the American Society of Clinical Oncology released clinical practice guidelines recommending prophylactic anticoagulation for hospitalized patients receiving chemotherapy.\textsuperscript{[15]} Therefore, starting in January 2010, we progressively implemented prophylactic anticoagulation with low-molecular-weight heparin (nadroparin 0.4 ml or equivalent). However, not all physicians integrated this guideline into their practice, and LMWH prophylaxis was prescribed at the individual physician's discretion.

STATISTICAL ANALYSIS

We performed a retrospective review of patients’ medical records. All thromboses or pulmonary embolisms, confirmed by imaging modality, were classified as events. Patient characteristics were tabulated and summarized as the median (range) value for continuous variables and frequency (percentage) for categorical variables. Fisher’s exact test was used for statistical analysis to compare VTE events between groups with and without prophylaxis.

The primary outcome was the overall incidence of VTE events occurring between Day 1 of the first cycle of first-line chemotherapy and Day 21 of the last cycle of first-line chemotherapy. Secondary outcomes were incidences of VTE events in various subgroups and overall survival.
Time to VTE was calculated from the start date of chemotherapy to the date of VTE diagnosis. The log-rank test was used to compare the differences between time to VTE between patients with and without prophylaxis.

Median follow-up was calculated as the median time of observation of the study patients. Overall survival was calculated from the start date of chemotherapy to the date of the last follow-up or death of the patient. The Kaplan-Meier method was used to estimate overall survival. The log-rank test was used to compare differences in survival between patients with and without prophylaxis. All calculations were performed using NCSS 2019 statistical software.[16]

Results

Patient characteristics

Our cohort included 353 chemotherapy-naive patients with GCTs treated with first-line chemotherapy (flow diagram). The patient characteristics are summarized in Table 1. The median age of patients at the time of enrollment was 32 years (ranging from 17 to 63 years). The majority of patients (75.9%) had nonseminomatous germ cell tumors. All patients received platinum-based chemotherapy.

VTE prophylaxis

LMWH prophylaxis was administered to 104 patients (29.5%) for the duration of hospitalization for chemotherapy, and 249 patients (70.5%) did not receive LMWH prophylaxis. Before January 2010, 7 out of 174 (4.0%) patients received LMWH prophylaxis, and 97 out of 179 (54.2%) patients treated after January 2010 received prophylaxis (flow diagram). The majority of patients (74.3%) receiving LMWH prophylaxis after January 2010 were stage II.B or higher. Heparin assays were not routinely performed to confirm the levels.

VTE events

In our study population, most VTE events occurred even before starting chemotherapy. We identified 41 out of 394 (10.4%) patients who developed VTE before starting treatment. These patients were excluded from the study (flow diagram).

During the study period, we observed 14 (4.0%) VTE events. Deep vein thrombosis was observed in 13 patients (3.7%), and one patient (0.3%) had pulmonary embolism. No visceral thromboses were observed (Supplementary Table S1). One event (7.1%) was fatal. In patients without prophylaxis, we documented eight events (3.2%), while six events (5.8%) were documented in patients receiving LMWH prophylaxis.
The difference was not statistically significant ($P = 0.37$). The data are summarized in Table 2. The median age of patients with and without VTE was 34 years vs. 31 years, $P = 0.24$.

Out of the fourteen VTE events, 8 events were symptomatic and 6 events were incidental. There were two symptomatic VTE events in patients receiving LMWH prophylaxis, and six symptomatic events occurred in patients without prophylaxis (75% vs. 33.3%, $P = 0.28$). In patients who experienced VTE, the median time to VTE was 28.5 days (15-83 days) in patients without prophylaxis and 53.5 days (1-92 days) in patients with prophylaxis (hazard ratio (HR) = 0.53, 95% CI 0.17 - 1.7, $P = 0.24$).

The incidence of VTE in patients without prophylaxis before 2010 was similar to the incidence of VTE in the subgroup of patients with prophylaxis after 2010, as well as in the subgroup analysis based on the IGCCCG risk group (Supplementary Table S2).

**Association between VTE prophylaxis and patient/tumor characteristics**

There were 12 VTE events in patients with nonseminomatous germ cell tumors (NSGCTs), and 2 events occurred in patients with seminoma. There were no statistically significant differences in VTE incidence between patients with and without prophylaxis based on tumor histology.

Twelve VTE events (3.8%) occurred in patients with gonadal tumors. Four events (4.4%) occurred in patients with prophylaxis, and eight events (3.5%) occurred in patients without prophylaxis. The difference was not statistically significant ($P = 0.75$). Two VTE events occurred in patients with extragonadal tumors. Both patients received LMWH prophylaxis. The difference was not statistically significant (0.0% vs. 14.3%, $P = 0.15$).

Out of the fourteen VTE events, five events occurred in patients with good risk according to the IGCCCG classification, three events occurred in patients with intermediate risk, and 6 events occurred in patients with poor risk. Patients with intermediate or poor risk were more likely to suffer VTE events than patients with good risk according to the IGCCCG classification (7.3% vs. 2.2%, $P = 0.02$). However, VTE incidence did not differ significantly in patients with and without prophylaxis for any of the risk groups. Similarly, the Khorana score and/or size of retroperitoneal lymph nodes had no impact on the effect of prophylactic anticoagulation (Table 2).

Out of the fourteen patients suffering VTE events, 8 patients received bleomycin, etoposide and cisplatin (BEP); 3 patients had a dose-dense regimen\[17\]; two patients received paclitaxel, bleomycin, etoposide and cisplatin; and one patient was treated with etoposide and cisplatin.

In patients receiving the BEP regimen, there were 2 VTE events (3.0%) in patients receiving LMWH prophylaxis and 6 events (3.3%) in patients without LMWH prophylaxis. In patients receiving chemotherapy regimens other than BEP, there were 4 events (10.8%) in patients with LMWH prophylaxis.
and 2 events (3.0%) in patients without prophylaxis. The difference was not statistically significant (p=0.1844).

**Association between overall survival and prophylactic anticoagulation**

The median follow-up of all patients was 71 months (0-224 months). The median follow-up of living patients was 122 months (1-224 months). There were 51 deaths (14.45%) in our study population. The 2- and 5-year overall survival rates of the study group were 87.99% (95% CI 84.49% – 91.49%) and 84.27% (95% CI 80.22% – 88.31%), respectively. There was no difference in overall survival in patients with or without prophylaxis (HR = 0.61, 95% CI 0.32-1.13; P = 0.0784) (Figure 1). The results are summarized in Table 3. Patients with extragonadal GCT and patients with NSGCT histology receiving VTE prophylaxis had significantly shorter survival than patients without prophylaxis (HR = 0.29, 95% CI 0.08-1.12; P = 0.0373, HR = 0.50, 95% CI 0.25-0.99; P = 0.0179, respectively) (Figure 2A and 2B). We also observed a trend toward shorter overall survival in patients receiving prophylaxis with chemotherapy regimens other than BEP (HR = 0.50, 95% CI 0.22-1.12; P = 0.0614).

We analyzed the incidence of treatment-related deaths (TRDs) in patients with primary extragonadal tumors and NSGCT histology based on LMWH prophylaxis (Supplementary Table S3). Treatment-related death was defined as death during first-line chemotherapy. Patients with extragonadal tumors receiving LMWH prophylaxis had a higher incidence of TRD than patients without prophylaxis (21.4% vs. 0.0%, P = 0.0556). Patients with NSGCT histology on LMWH prophylaxis also had a higher incidence of TRD than patients without prophylaxis (10.9% vs. 3.9%, P = 0.0552). In the subgroup analysis of patients with NSGCT histology, we found that this trend was driven by TRD in patients with primary extragonadal tumors.

**Incidence of major bleeding during VTE prophylaxis**

In our cohort, there were 13 patients who suffered major bleeding (grade 3-5). There were 7 patients (2.8%) who received no prophylaxis, and 6 patients (5.8%) received LMWH prophylaxis. The difference was not statistically significant (P = 0.22).

**Discussion**

In the present study, we examined the relationship between prophylactic anticoagulation during chemotherapy and the incidence of VTE events as well as the association between prophylactic anticoagulation and the overall survival of patients with GCT treated with first-line chemotherapy. To assess the effect of prophylactic anticoagulation on the incidence of VTE events, we included only events occurring during first-line chemotherapy when patients were also receiving LMWH prophylaxis.
We have observed that most VTE events occur even before the initiation of chemotherapy. There was a 4% incidence of VTE events occurring during chemotherapy. The observed incidence of VTE events is in line with the incidences reported in the literature.[6, 8, 10, 18-20] However, there is a wide variation in the reported incidences.[21] While the lowest reported incidence is 2%, in a different study, there was an incidence of thromboembolic events of 23.7%.[8, 20] A significant part of this variation is probably caused by different inclusion criteria, such as including arterial events, including patients with VTE events before the start of chemotherapy, and events occurring several months after chemotherapy. The small number of patients in some studies may also contribute to this variability.

We observed no significant differences in VTE incidence between patients with and without LMWH prophylaxis. While there have been several studies assessing VTE incidence and identifying VTE risk factors in patients with GCT, most of them included only a small number of the study patients with LMWH prophylaxis. We did not observe a beneficial effect of prophylactic anticoagulation even in patients with recognized risk factors for VTE, including a high Khorana score and/or increased retroperitoneal lymph node size.[14, 22]

Solari et al. compared the incidence of thromboembolic events in patients receiving limited and extended LMWH prophylaxis. Limited prophylaxis was administered only during hospitalization. Extended prophylaxis was administered daily from Day 1 of the first cycle to Day 21 of the last cycle of chemotherapy. They did not observe significant differences between these two groups. However, their study did not include a control group with no prophylaxis; therefore, the effect of LMWH prophylaxis cannot be assessed. Paradoxically, the incidence of thromboembolic events reported in their study (23.7%) was much higher than in other studies.[20] However, arterial events were also included in their analysis. Gizzi et al. also compared the VTE incidence in patients with GCT with and without LMWH prophylaxis. In their study, prophylaxis was administered to a subgroup of patients with risk factors for VTE (elevated lactate dehydrogenase or high body surface area). They observed no statistically significant difference in VTE incidence between the two groups. However, neither the type of LMWH used nor the dosing of prophylaxis were mentioned.[12]

Unexpectedly, there was a trend toward shorter overall survival in our patients who received LMWH prophylaxis. On further analysis, we found a significantly shorter overall survival in patients receiving LMWH prophylaxis with NSGCT histology or extragonadal tumor location.

A prospective study assessing the effect of prophylactic anticoagulation in patients with GCT receiving chemotherapy compared to no prophylaxis is lacking. However, the data available suggest that LMWH prophylaxis does not offer the expected benefits in terms of decreased incidence of VTE events in patients with GCT.[12, 20] In contrast, our data suggest that administering LMWH prophylaxis might confer a higher risk for treatment-related deaths in patients with extragonadal tumors. Given the small number of patients with extragonadal tumors included in our study and selection bias, this result is only hypothesis generating. Further research should focus on examining the possible association between LMWH and increased incidence of TRDs. In October 2019, the American Society of Clinical Oncology
published an updated guideline on the use of thromboprophylaxis in patients with cancer. According to this guideline, hospitalized patients with active malignancy without additional risk factors may be offered pharmacologic thromboprophylaxis. However, routine use of thromboprophylaxis in patients with cancer hospitalized solely for administration of chemotherapy is no longer recommended.[23]

To the best of our knowledge, this is the largest study evaluating the effect of LMWH prophylaxis on VTE incidence in patients with GCT receiving chemotherapy. Our study has several limitations. First, LMWH prophylaxis was not random, possibly causing selection bias. It is possible that patients at higher risk for VTE were given thromboprophylaxis more frequently, which could in turn obscure the effect of thromboprophylaxis. However, the incidence of VTE in patients without prophylaxis before 2010 was similar to the incidence of VTE in the subgroup of patients with prophylaxis after 2010, as well as in the subgroup analysis based on the IGCCCG risk group (Supplementary Table S1). This supports the conclusion of no beneficial effect of prophylaxis in patients with GCT. Second, the study has a retrospective design. Some VTE events could have been missed as a result of incomplete medical records.

**Conclusion**

In conclusion, in this large retrospective analysis, we showed that LMWH prophylaxis was not associated with decreased VTE incidence. Moreover, there was a higher incidence of treatment-related deaths in patients with extragonadal tumor location. Taking into account these data, LMWH prophylaxis during hospitalization should not be used in patients with GCT receiving chemotherapy.

**Abbreviations**

BEP – bleomycin, etoposide, cisplatin

CI – confidence interval

GCT – germ cell tumor

HR – hazard ratio

IGCCCG - International Germ Cell Cancer Collaborative Group

LMWH – low-molecular-weight heparin

NSGCT - nonseminomatous germ cell tumor

RR – relative risk

TRD – treatment-related death

VTE – venous thromboembolism
Declarations

Ethics approval and consent to participate The Institutional Review Board of the National Cancer Institute, Bratislava, Slovakia, approved this study and granted a waiver of consent form for the collection, analysis and publication of the retrospectively obtained and anonymized data for this noninterventional study.

Consent for publication

Not applicable.

Availability of data and materials

The dataset supporting the conclusions of this article is included within the article.

Competing interests

None declared.

Funding

This work was supported by the VEGA Grant Agency of the Slovak Republic (VEGA 1/0043/18), the Slovak Research and Development Agency (grant APVV-15-0086) and the Ministry of Health (MZ SR 2018/39-LFUK-13). The sponsors played no direct role in the study.

Authors’ contributions

NH, MCh, KR, KK, JO, PP, VDE, ZSM, JM and MM participated in the conception and design, acquisition, analysis and interpretation of data. NH drafted the article, and all authors revised it critically for important intellectual content. All the authors read this manuscript and gave final approval of the version to be published.

Acknowledgments
We would like to acknowledge Mrs. Daniela Slackova from the Population Registry of Slovak Republic for help with updating the patient databases and Dr. Maria Reckova for discussions and critical input. We would like to acknowledge Dr. Daniela Světlovska for administration support.

References

1. Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H: Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 2006, 118(12):3099-3111.

2. Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S: Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 2015, 33(5):623-631.

3. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 2019, 69(1):7-34.

4. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC: Epidemiology of cancer-associated venous thrombosis. Blood 2013, 122(10):1712-1723.

5. Hisada Y, Mackman N: Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017, 130(13):1499-1506.

6. Piketty AC, Fléchon A, Laplanche A, Nouyrigat E, Droz JP, Théodore C, Fizazi K: The risk of thromboembolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005, 93(8):909-914.

7. Levitan N, Dowlati A, Remick SC, Tахsildar HI, Sivinski LD, Beyth R, Rimm AA: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999, 78(5):285-291.

8. Honecker F, Koychev D, Luhmann AD, Langer F, Dieckmann KP, Bokemeyer C, Oechsle K: Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy. Onkologie 2013, 36(11):663-668.

9. Bezan A, Posch F, Ploner F, Baumhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H et al: Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One 2017, 12(4):e0176283.

10. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, Cleton FJ, Osanto S: Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000, 18(10):2169-2178.

11. Paffenholz P, Grein K, Heidegger I, Nestler T, Grabbert M, Salem J, Hellmich M, Pfister D, Heidenreich A: Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J Urol 2019, 37(9):1907-1916.

12. Gizzi M, Oberic L, Massard C, Poterie A, Le Teuff G, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A et al: Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer 2016, 69:151-157.
13. Akl EA, Kahale LA, Hakoum MB, Matar CF, Sperati F, Barba M, Yosuico VED, Terrenato I, Synnot A, Schunemann H: Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst Rev 2017, 9:Cd006652.

14. Khorana AA, Francis CW, Culakova E, Lyman GH: Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005, 104(12):2822-2829.

15. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H et al: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25(34):5490-5505.

16. NCSS 2019 Statistical Software. In. Kaysville, Utah, USA: NCSS, LLC; 2019.

17. Fizazi K, Pagliaro L, Laplanche A, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F et al: Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 2014, 15(13):1442-1450.

18. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H: High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011, 29(25):3466-3473.

19. Cantwell BM, Mannix KA, Roberts JT, Ghani SE, Harris AL: Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet 1988, 2(8619):1086-1087.

20. Solari L, Kronig M, Ihorst G, Drognitz K, Heinz J, Jilg CA, Schultze-Seemann W, Engelhardt M, Waller CF: High Rates of Thromboembolic Events in Patients with Germ Cell Cancer Undergoing Cisplatin-Based Polychemotherapy. Urol Int 2016, 96(4):399-405.

21. Robinson AG, Wei X, Karim S, Raphael MJ, Bedard PL, Booth CM: Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study. Clin Oncol (R Coll Radiol) 2020.

22. Srikanthan A, Tran B, Beausoleil M, Jewett MA, Hamilton RJ, Sturgeon JF, O’Malley M, Anson-Cartwright L, Chung PW, Warde PR et al: Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol 2015, 33(6):582-587.

23. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW et al: Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019;Jco1901461.

Tables

Table 1 Patient characteristics
|                          | N  | %  |
|--------------------------|----|----|
| **All**                  | 353| 100|
| **Histology**            |    |    |
| Seminoma                 | 79 | 22.4|
| NSGCT                    | 268| 75.9|
| Unknown                  | 6  | 1.7 |
| **Primary tumor**        |    |    |
| Gonadal                  | 318| 90.1|
| Extragonadal             | 35 | 9.9 |
| Retroperitoneum          | 22 | 6.2 |
| Mediastinum              | 10 | 2.8 |
| Brain                    | 2  | 0.6 |
| Unknown                  | 1  | 0.3 |
| **Stage**                |    |    |
| I.A/B                    | 38 | 10.8|
| I.S                      | 22 | 6.2 |
| II.A                     | 30 | 8.5 |
| II.B                     | 47 | 13.3|
| II.C                     | 44 | 12.5|
| III.A                    | 43 | 12.2|
| III.B                    | 42 | 11.9|
| III.C                    | 87 | 24.6|
| **IGCCCG risk group**    |    |    |
| Stage IA/B               | 38 | 10.8|
| Good                     | 192| 54.4|
| Intermediate             | 46 | 13.0|
| Poor                     | 77 | 21.8|
| **Treatment regimen**    |    |    |
| BEP                      | 250| 70.8|
| Other                    | 103| 29.2|
| **Follow-up status**     |    |    |
| Alive                    | 300| 84.99|
| Exitus                   | 51 | 14.45|
| Unknown                  | 2  | 0.57|
| **Khorana score**        |    |    |
| 1                        | 231| 65.44|
| 2                        | 73 | 20.68|
| 3                        | 44 | 12.46|
| 4                        | 5  | 1.42 |
| **N-stage**              |    |    |
| N0                       | 84 | 23.80|
| N1                       | 47 | 13.31|
| N2                       | 75 | 21.25|
| N3                       | 136| 38.53|
| Unknown                  | 11 | 3.12|

Table 2 VTE events
|                          | No prophylaxis | VTE prophylaxis | p value |
|--------------------------|----------------|-----------------|---------|
|                          | N   | %    | N    | %    |         |
| All VTE events           | 8/249 | 3.2  | 6/104 | 5.8  | 0.3681  |
| Incidental events        | 2/8  | 25.0 | 4/6   | 66.7 | 0.2774  |
| Symptomatic events       | 6/8  | 75.0 | 2/6   | 33.3 |         |
| **Histology**            |      |      |       |      |         |
| Seminoma                 | 1/45 | 2.2  | 1/34  | 2.9  | 1.0000  |
| NSGCT                    | 7/197| 3.4  | 5/64  | 7.8  | 0.1653  |
| **Primary tumor location** |    |      |       |      |         |
| Gonadal                  | 8/228| 3.5  | 4/90  | 4.4  | 0.7461  |
| Extragonadal             | 0/21 | 0.0  | 2/14  | 14.3 | 0.1529  |
| **IGCCCG risk group**    |      |      |       |      |         |
| Stage IA/B               | 0/34 | 0.0  | 0/4   | 0.0  | 1.0000  |
| Good                     | 4/135| 3.0  | 1/57  | 1.8  | 1.0000  |
| Intermediate             | 1/31 | 3.2  | 2/15  | 13.3 | 0.2444  |
| Poor                     | 3/49 | 6.1  | 3/28  | 10.7 | 0.6622  |
| **Chemotherapy regimen** |      |      |       |      |         |
| BEP                      | 6/183| 3.3  | 2/67  | 3.0  | 1.0000  |
| Other                    | 2/66 | 3.0  | 4/37  | 10.8 | 0.1844  |
| **Khorana score**        |      |      |       |      |         |
| 1                        | 6/171| 3.5  | 1/60  | 1.7  | 0.6800  |
| 2                        | 2/52 | 3.8  | 1/21  | 6.4  | 1.0000  |
| 3                        | 0/22 | 0.0  | 4/22  | 1.8  | 0.1078  |
| 4                        | 0/4  | 0.0  | 0/1   | 0.0  | 1.0000  |
| **N-stage**              |      |      |       |      |         |
| N0                       | 1/70 | 1.4  | 1/12  | 8.3  | 0.2871  |
| N1                       | 2/38 | 5.3  | 1/6   | 16.7 | 0.3907  |
| N2                       | 1/43 | 2.3  | 0/31  | 0.0  | 1.0000  |
| N3                       | 3/85 | 3.5  | 4/44  | 9.1  | 0.2426  |

Table 3 Overall survival
|                                | VTE prophylaxis | N     | HR  | Lower 95% CI | Upper 95% CI | p value |
|--------------------------------|----------------|-------|-----|--------------|--------------|---------|
| **All patients**               | 0/1            | 249/104 | 0.61 | 0.32         | 1.13         | 0.0784  |
| **IGCCCG risk group**          |                |       |     |              |              |         |
| Stage IA/B                     | 0/1            | 34/4  | 0.00 | 0.00         | 0.00         | 0.6532  |
| Good                           | 0/1            | 135/57 | 1.09 | 0.12         | 9.99         | 0.9425  |
| Intermediate                   | 0/1            | 31/15 | 0.72 | 0.06         | 9.36         | 0.7836  |
| Poor                           | 0/1            | 49/28 | 0.69 | 0.36         | 1.33         | 0.2368  |
| **Chemotherapy regimen**       |                |       |     |              |              |         |
| BEP                            | 0/1            | 183/67 | 0.94 | 0.37         | 2.42         | 0.8975  |
| Other                          | 0/1            | 66/37 | 0.5  | 0.22         | 1.12         | 0.0614  |
| **Tumor histology**            |                |       |     |              |              |         |
| Seminoma                       | 0/1            | 45/34 | 0.58 | 0.03         | 10.34        | 0.6988  |
| NSGCT                          | 0/1            | 204/64 | 0.5  | 0.25         | 0.99         | 0.0179  |
| **Primary tumor location**     |                |       |     |              |              |         |
| Gonadal                        | 0/1            | 228/90 | 0.76 | 0.38         | 1.53         | 0.4178  |
| Extranodal                     | 0/1            | 21/14 | 0.29 | 0.08         | 1.12         | 0.0373  |
| **Khorana score**              |                |       |     |              |              |         |
| 1                              | 0/1            | 171/60 | 0.83 | 0.25         | 2.76         | 0.7555  |
| 2                              | 0/1            | 52/21  | 0.71 | 0.23         | 2.23         | 0.5272  |
| 3                              | 0/1            | 22/22  | 0.69 | 0.26         | 1.83         | 0.4461  |
| 4                              | 0/1            | 4/1    | 0.38 | 0.02         | 8.45         | 0.3508  |
| **N-stage**                    |                |       |     |              |              |         |
| N0                             | 0/1            | 71/13  | 0.67 | 0.12         | 3.94         | 0.6161  |
| N1                             | 0/1            | 40/7   | 0.54 | 0.03         | 8.24         | 0.5824  |
| N2                             | 0/1            | 44/31  | 0.42 | 0.07         | 2.52         | 0.3179  |
| N3                             | 0/1            | 88/48  | 0.88 | 0.38         | 2.00         | 0.7475  |

**Figures**

![Survival Plot](image)

- **OS**:Overall Survival
- **Survival**:Percentage of patients surviving at each time point
- **LMWH**:
  - 0
  - 1
**Figure 1**

Kaplan–Meier estimates of probabilities of overall survival according to VTE prophylaxis in testicular germ cell tumor patients (n = 353), HR = 0.61, 95% CI 0.32-1.13; P = 0.0784, 0 – no prophylaxis, 1 - prophylaxis

**Figure 2**

2A Kaplan–Meier estimates of probabilities of overall survival according to VTE prophylaxis in non-seminomatous germ cell tumor patients (n = 268), HR = 0.29, 95% CI 0.08 - 1.12; P = 0.0373, 0 – no prophylaxis, 1 - prophylaxis. 2B Kaplan–Meier estimates of probabilities of overall survival according to VTE prophylaxis in extragonadal germ cell tumor patients (n = 35), HR = 0.50, 95% CI 0.25-0.99; P = 0.0179, 0 – no prophylaxis, 1 – prophylaxis.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Flowdiagramandtables.docx
- VTEwSupplementarytablesrevised182020Clean.docx